SMITHKLINE BECKMAN's CORPORATE CONTRACT WITH HCA
Executive Summary
SMITHKLINE BECKMAN's CORPORATE CONTRACT WITH HCA covers three diverse product and service areas: SmithKline Bio-Science Laboratories, Allergan, and Beckman Instruments. Bio-Science will provide Hospital Corporation of America member institutions with clinical lab testing, Allergan will supply ophthalmic medications, and Beckman will provide diagnostic instruments and reagents. The corporate agreement expands on an earlier contract between HCA and Smith Kline & French Laboratories. Under the earlier accord, SmithKline is supplying HCA hospitals with cephalosporin antibiotic products, and Tagamet. While a number of SmithKline's businesses have purchasing contracts with hospitals, the company as a whole has only a few "corporate" alliances involving two or more SmithKline subsidiaries. Under the corporate agreement, SmithKline is designated as the primary supplier for the covered product areas. The firm did not say whether the agreement calls for minimum purchases by HCA. The contract took effect Jan. 1 and will run for three years with an option to renew. The HCA contract was arranged by SmithKline's corporate accounts office, which has been headed since last November by Vice President for Corporate Accounts Ronald Stewart. Since its start up in late 1985, the corporate accounts office has negotiated several other multi-hospital customers, including Humana, Prennier Hospital, Alliance and Universal Health. Stewart is a 23 year SmithKline veteran with a background in marketing and corporate personnel. Before taking over the corporate accounts position, he managed state government affairs for SK&F Labs.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth